Pluvicto Radiopharmaceutical Therapy
A targeted, PSA-based therapy for advanced prostate cancer, delivering precision treatment to extend both survival and quality of life, right here in Boca Raton.
Expert Cancer Care You Can Trust
At Lynn Cancer Institute, we are among the first in South Florida to offer Pluvicto, an FDA-approved radioligand therapy for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). Delivered via infusion, this precision therapy directly targets cancer cells while minimizing damage to normal tissue. According to Dr. Michael Kasper, it can extend survival and preserve quality of life for patients with advanced prostate cancer.
Our Approach
We begin with a PSMA PET scan to confirm eligibility. Pluvicto is then delivered in a series of monthly infusions, typically spanning several months, under close monitoring by our interdisciplinary oncology team. Treatment is coordinated carefully to ensure both efficacy and patient comfort.
Meet Our Specialists
Our specialists in prostate cancer treatment are trained in using targeted therapies like Pluvicto. At LCI, your care is guided by a team of board-certified experts who understand both the science and the emotional support needed to navigate treatment.
Expert Care Close to Home
Frequently Asked Questions
-
It binds to PSMA on prostate cancer cells, delivering targeted radiation directly to those cells.
-
Typically via infusion every six weeks, for up to six cycles.
-
Patients with PSMA-positive mCRPC who have previously undergone hormone therapy, and now earlier-stage disease due to expanded FDA approval.
-
Mainly fatigue, nausea, dry mouth, anemia, and decreased appetite.
Pioneering the Cures of Tomorrow
Lynn Cancer Institute brings world-class radiopharmaceutical therapy closer to home, enabling Palm Beach County patients to access cutting-edge mCRPC care.